论文信息 - Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. - 字舞流文

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.

M. Birrer | U. Matulonis | N. Horowitz | Hang Lee | P. Konstantinopoulos | R. Penson | C. Krasner | S. Campos | Karan R. Chadda | Chantay Young | Antonella M D'Ascanio